Insider Buying: OraSure Technologies, Inc. (NASDAQ:OSUR) Director Purchases 47,659 Shares of Stock

OraSure Technologies, Inc. (NASDAQ:OSUR) Director John P. Kenny acquired 47,659 shares of the stock in a transaction on Thursday, February 27th. The shares were acquired at an average price of $3.17 per share, for a total transaction of $151,079.03. Following the acquisition, the director now owns 70,915 shares of the company’s stock, valued at approximately $224,800.55. The trade was a 204.93 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

OraSure Technologies Stock Up 11.2 %

OSUR stock opened at $3.48 on Friday. The firm has a market cap of $259.59 million, a PE ratio of 23.20 and a beta of 0.05. The business has a 50 day moving average of $3.78 and a 200-day moving average of $4.00. OraSure Technologies, Inc. has a 12-month low of $2.68 and a 12-month high of $7.81.

Hedge Funds Weigh In On OraSure Technologies

Several institutional investors have recently modified their holdings of the business. Mackenzie Financial Corp lifted its stake in OraSure Technologies by 229.4% in the fourth quarter. Mackenzie Financial Corp now owns 134,051 shares of the medical instruments supplier’s stock valued at $484,000 after purchasing an additional 93,359 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new position in OraSure Technologies in the fourth quarter valued at approximately $277,000. Two Sigma Advisers LP lifted its stake in OraSure Technologies by 36.9% in the fourth quarter. Two Sigma Advisers LP now owns 97,200 shares of the medical instruments supplier’s stock valued at $351,000 after purchasing an additional 26,200 shares during the last quarter. Two Sigma Investments LP purchased a new position in OraSure Technologies in the fourth quarter valued at approximately $552,000. Finally, Systematic Financial Management LP lifted its stake in OraSure Technologies by 33.7% in the fourth quarter. Systematic Financial Management LP now owns 1,673,609 shares of the medical instruments supplier’s stock valued at $6,042,000 after purchasing an additional 421,497 shares during the last quarter. 93.50% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered OraSure Technologies from a “buy” rating to a “hold” rating in a report on Saturday, February 22nd.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.